2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2839 Impact of insurance type and social vulnerability index on allogeneic hematopoietic cell transplant outcomes at an urban academic center

Lauren Laufer, MD, Abigail Kim2, Myung Shin Sim3, Caspian Oliai, MD4, Steven Tsai, MD5, Patricia Young, MD6, Christopher Seet, MD, PhD7, Theodore Moore, MD8, Satiro DeOliveira9, Levanto Schachter, MS, DO10, Sarah M. Larson, MD11, Gary J. Schiller, MD12, Wanxing board Chai-Ho, MD13
1 UCLA David Geffen School of Medicine, Department of Medicine, Los Angeles, United States
2 UCLA Volunteer Program, Granada Hills Charter High School, Class of 2027, Los Angeles, United States
3 Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, United States
4 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
5 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
6 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
7 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
8 UCLA David Geffen School of Medicine, Department of Pediatrics, Los Angeles, United States
9 UCLA David Geffen School of Medicine, Department of Pediatrics, Los Angeles, United States
10 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
11 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
12 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States
13 UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, Los Angeles, United States

Background: Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for hematologic stem cell disorders, yet disparities in access and outcomes persist across socioeconomic and demographic groups. Prior work has shown that racial/ethnic minorities, insurance types, and those residing in socially disadvantaged areas are less likely to undergo HCT and may experience inferior outcomes. The Social Vulnerability Index (SVI), a composite measure of community-level disadvantage, has similarly been linked to inferior non-relapse mortality (NRM) and survival after HCT. We set out to examine how sociodemographic factors including insurance type and SVI relate to transplant outcomes at an urban academic center.

Methods: We conducted a retrospective cohort study of patients who underwent allogeneic HCT at UCLA between 1/1/2019–6/30/2026. Data were abstracted from the electronic health record and institutional transplant database, including demographics, insurance type (government (GI: Medicare/Medi-Cal/CenCal), commercial/private (CP), or managed care (MC)), SVI by residential zip code, and disease/transplant characteristics. Outcomes included listing duration to transplant, overall survival (OS), relapse, post-transplant re-hospitalization and length of stay (LOS). Comparisons used ANOVA, chi-square, and multivariable Cox proportional hazards analysis.

Results: Among 468 patients, 195 (41.7%) had GI, 148 (31.6%) had CP, and 125 (26.7%) had MC. Overall, median age of patients were 47.5 years old, 79.9% of patients were <65 years old, though this varied significantly by insurance (GI 70.8%, CP 89.9%, MC 82.4%. p<0.0001). AML and MDS account for 53.63% transplant diagnosis. Ethnicity and disease type did not differ significantly by insurance. HCT-comorbidity index (HCT-CI) data was available in 373 patients. It was higher in GI (mean 2.39) than CP (1.94) and MC (1.85, p=0.043). In patients ≥65 years old, 26.6% had HCT-CI >3, whereas only 13.4% patients <65 years old had HCT-CI >3 (p<0.0001).  Time to transplant did not differ by insurance type (p=0.90). GI patients had significantly longer total hospital LOS (mean 59.6 days) than CP (42.7) and MC (47.6, p=0.0004), more hospitalizations within 1 year (1.66 vs 1.06 CP and 1.19 MC, p=0.004). Mean SVI was highest in MC (0.68), followed by GI (0.62) and CP (0.51, p<0.0001). OS across the full follow-up period differed significantly by insurance (median follow up in days were 941, 752 and 1020 in GI, CP and MC, log-rank p=0.029), highest in MC (81.6%), followed by CP (75.68%), then GI (67.18%). One-year OS showed a similar but nonsignificant trend (84.1% GI, 83.1% CP, 90.4% MC. p=0.17). One-year NRM did not differ by insurance. SVI category was not independently associated with OS. In the final parsimonious Cox model, both HCT-CI (HR 1.849, 95% CI 1.175-2.908, p=0.0078) and government insurance (HR 1.906, 95% CI 1.168–3.112, p=0.0099, vs. MC) were independently associated with worse overall survival. Separately, 405 patients were removed from the transplant waiting list prior to HCT, most commonly for medical reasons or patient/physician decision (42% and 22%). Twenty-two patients (5.4%) were removed specifically for insurance-related reasons, and 8 of these (36.4%) had MC insurance, though this difference did not reach statistical significance (p=0.65).

Conclusions: Prior literature suggests high SVI increases barriers to transplant and NRM. In our cohort, insurance type, rather than SVI, was the more consistent marker of disparity. Government-insured patients had longer hospital stays, more readmissions, and worse survival despite not having the highest SVI, potentially reflecting greater HCT-CI as an independent risk factor. Notably, MC patients, despite the highest SVI, had the best survival, possibly reflecting younger age and strong institutional social work support. Worse outcomes with GI may also reflect factors not captured here such as difficult hospital dispositions or worse medication coverage. These findings emphasize the importance of continued, robust social support for vulnerable patients and suggest that those with GI or high HCT-CI may benefit from additional pre-transplant risk stratification and post-transplant support. Future analyses include further GI sub-categorizations involving age and the above risk factors to determine concrete areas for intervention.

Lauren Laufer, MD: No relevant conflicts of interest to declare.